Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The
introduction of highly sensitive immunoassays led to a rapid increase in the number of …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown
promising results, there is increasing evidence suggesting that understanding alternative …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer's disease (AD). However, plasma …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

The advent of proteomics offers an unprecedented opportunity to predict dementia onset.
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

Introduction This study involved a parallel comparison of the diagnostic and longitudinal
monitoring potential of plasma glial fibrillary acidic protein (GFAP), total tau (t‐tau) …

Neuroinflammation play an important role in Alzheimer's disease pathogenesis. Advances in
molecular imaging using positron emission tomography have provided insights into the time …